Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Launched by NANTES UNIVERSITY HOSPITAL · Mar 19, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called von Willebrand disease, which affects how blood clots. Researchers want to understand how certain proteins related to blood vessel growth (called angiogenesis) behave in people with this disease. They will study 70 patients to see if there are specific markers that help explain the symptoms, especially bleeding problems linked to abnormal blood vessel formations.

To participate, patients must have von Willebrand disease confirmed by genetic testing and not be on treatments that could affect blood vessel growth. Healthy individuals with normal blood clotting and no bleeding issues can also join as a comparison group. Participants will provide blood samples for the study and will receive detailed information about the trial, including their right to refuse the use of their samples. This research could help improve understanding and treatment of von Willebrand disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For patients:
• • Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
• • Lack of treatment that could interfere with angiogenesis.
• • Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
• For the control:
• • Patient with a normal coagulation report
• • Absence of abnormal hemorrhagic symptoms
• • Lack of notion of angiodysplasia.
• • Lack of treatment that could interfere with angiogenesis.
• • Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
• Exclusion Criteria:
• • Patient under guardianship or curatorship.
• • Pregnant and lactating women.
• • Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
• • Treatment which may interfere with angiogenesis.